公开(公告)号：EP3816289A1

公开(公告)日：2021-05-05

申请号：EP19823371.0

申请日：2019-06-19

申请人： Pharma Foods International Co., Ltd.

发明人： SAITO, Kenji ,  SAKATA, Tomoko ,  KAWANOBE, Takaaki ,  KOGA, Keita

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P19/02 ,  C07K7/08 ,  C07K16/40 ,  C12N9/99 ,  C12N15/63 ,  C12P21/08

摘要： To obtain an anti-PAD2 antibody having excellent PAD2 inhibitory activity. Provided is an anti-PAD2 antibody that specifically binds to positions 341 to 357 of PAD2. Also provided is an anti-PAD2 antibody that specifically binds to a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1.

公开(公告)号：EP4296357A1

公开(公告)日：2023-12-27

申请号：EP22756287.3

申请日：2022-02-18

申请人： Mitsubishi Tanabe Pharma Corporation ,  Pharma Foods International Co., Ltd.

发明人： MIYAMOTO, Yuya ,  WADA, Koichi ,  IMURA, Yuichi ,  SAITO, Kenji ,  SAKATA, Tomoko ,  SHIGEMITSU, Takanari

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P13/12 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P43/00 ,  C07K16/40 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

摘要： Provided is an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1, HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, HCDR3 comprises an amino acid sequence of SEQ ID NO: 3, LCDR1 comprises an amino acid sequence of SEQ ID NO: 4, LCDR2 comprises an amino acid sequence of SEQ ID NO: 5, and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6.

公开(公告)号：EP3266872A1

公开(公告)日：2018-01-10

申请号：EP16761721.6

申请日：2016-03-07

申请人： Public University Corporation Yokohama City University ,  Public University Corporation Nagoya City University ,  Pharma Foods International Co., Ltd.

发明人： SATO, Mamoru ,  YAMADA, Michiyuki ,  KANAZAWA, Satoshi ,  TOYOURA, Masayoshi ,  SHOYA, Yuji ,  SAITO, Kenji ,  YAMAZAKI, Chihiro

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P19/02 ,  C07K16/40 ,  C12N9/99 ,  C12P21/08

CPC分类号： C07K16/40 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/99 ,  C12N15/09 ,  C12Y305/03015 ,  A61K2300/00

摘要： Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0 × 10 -9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

摘要翻译： 提供具有优异性能的抗PAD4抗体和用于治疗RA的优良方法。 所用的抗PAD4抗体特异性结合含有PAD4位置345,347和348的表位。 这些抗PAD4抗体可以抑制PAD4的瓜氨酸活性。 另外，这些抗PAD4抗体可具有9.0×10 -9或更低的KD（M）。 任选地，组合使用抗PAD4抗体和TNFα抑制剂。